Altre lingue Astellas Pharma Inc.

Azioni

4503

JP3942400007

Prodotti farmaceutici

Mercato chiuso - Japan Exchange Altri mercati azionari 07:30:00 13/12/2024			Variaz. 5gg	Var. 1 gen.
1.556,50 ^JPY	-1,58%		-1,55%	-7,68%

19/11	Astellas Pharma Inc. fornisce un aggiornamento sulla domanda supplementare di nuovi farmaci per IZERVAY (Avacincaptad Pegol Soluzione Intravitreale)	CI
31/10	Astellas registra una perdita sui cambi di 12,2 miliardi di yen	MT

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Astellas Pharma Inc. Provides Update on IZERVAY (Avacincaptad Pegol Intravitreal Solution) Supplemental New Drug Application	19/11
Astellas Reports 12.2 Billion Yen Foreign Exchange Loss	31/10
US FDA Approves Astellas' VYLOY for Gastric Cancer Treatment	22/10
Astellas VYLOY Approved by U.S. FDA for Treatment of Advanced Gastric and GEJ Cancer	21/10
Astellas Pharma's Cancer Drug Vyloy Gets FDA Approval	18/10
Roche erhält US-Zulassung für Begleitdiagnostikum bei Magenkrebs	18/10
Roche Gets FDA Approval for Cancer Diagnostic Test	18/10
Roche erhält FDA-Zulassung für Krebs-Begleitdiagnostikum	18/10
Roche: la FDA homologue un diagnostic pour le cancer de l'estomac	18/10
Astellas Pharma Inc. Vyloy? (Zolbetuximab-Clzb) Approved by U.S. Fda for Treatment of Advanced Gastric and Gej Cancer	18/10
Pfizer's TALZENNA in Combination with XTANDI Prolongs Overall Survival in Phase 3 TALAPRO-2 Trial	11/10
Pfizer Reports Positive Results From Study of Talzenna, Xtandi Combination to Treat Prostate Cancer	10/10
Roche Secures CE Marking for Gastric Cancer Companion Diagnostic Test	10/10
Roche erhält CE-Zertifizierung für erstes Begleitdiagnostikum bei Magenkrebs	10/10
Takeda Forms Joint Venture With Astellas, Sumitomo Mitsui to Develop Early-Drug Discovery Programs in Japan	09/10
Myrbetriq® Patent Invalidated On Grounds Not Asserted By Any Party Violating Party Presentation Principle	04/10
Global markets live: Barclays, Chevron, Boeing, Intel, Visa...	24/09
Astellas Pharma Gets Nod for PADCEV and KEYTRUDA Combination Therapy for Urothelial Carcinoma	24/09
Quand la Chine s'éveillera	24/09
En Direct des Marchés : Qui succèdera à Tavares chez Stellantis ? Legrand 2030 et rachats en série	24/09
Nikkei Gains as BOJ Governor Signals Steady Inflation Rise by 2026	24/09
Astellas Pharma Inc. Announces Japan's Ministry of Health, Labour and Welfare Approves PADCEVTM with KEYTRUDA (Pembrolizumab) for First-Line Treatment of Radically Unresectable Urothelial Carcinoma	24/09
Bolsa de Madrid: Cuando China despierta	24/09
Astellas Wins European Approval for VYLOY in Targeted Gastric Cancer Therapy	24/09
Astellas Pharma Inc. Receives Approval from the European Commission for VYLOY in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer	24/09

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Astellas Pharma Inc.

Azioni

4503

JP3942400007

Prodotti farmaceutici

Altre lingue

Filtri